Welcome to our dedicated page for bioAffinity Tech SEC filings (Ticker: BIAF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
bioAffinity Technologies is turning flow cytometry into frontline lung-cancer diagnostics, but the science that excites clinicians also makes its SEC paperwork dense. Whether you are hunting for trial-phase milestones, revenue from licensing CyPath Lung, or shifts in cash burn, scanning hundreds of pages is tedious. Investors often ask, “Where can I see bioAffinity Technologies insider trading Form 4 transactions?” or “How do I read the latest bioAffinity Technologies quarterly earnings report 10-Q filing?”
Stock Titan’s AI-powered engine answers those questions instantly. We stream every Form 8-K so material events are explained, flag bioAffinity Technologies Form 4 insider transactions real-time, and deliver concise notes that turn R&D footnotes into plain English. Need to compare dilution risk? Our summaries point you to the exact section of the bioAffinity Technologies annual report 10-K simplified. Looking for management pay? The platform links directly to the bioAffinity Technologies proxy statement executive compensation and highlights key numbers. In one dashboard you get bioAffinity Technologies SEC filings explained simply, complete with cross-linked exhibits. That means understanding bioAffinity Technologies SEC documents with AI happens in minutes, not days.
Use cases are practical: monitor bioAffinity Technologies executive stock transactions Form 4 before pivotal study readouts; track segment spending via each bioAffinity Technologies earnings report filing analysis; or get alerts when a new bioAffinity Technologies 8-K material events explained hits EDGAR. All filings—10-K, 10-Q, S-1, 13G—arrive in real time and come with clear, expert context. By turning complex disclosures into actionable insights, our platform lets you focus on decisions rather than document hunts.
bioAffinity Technologies announced it has regained compliance with Nasdaq listing standards. A Nasdaq Hearings Panel found the company in compliance with Listing Rule 5550(a)(2) (the Minimum Bid Price Rule) and 5550(b)(1) (the Minimum Stockholders’ Equity Rule).
The company will be under a mandatory panel monitor for one year. If, during that period, it falls out of compliance with the Minimum Stockholders’ Equity Rule, it will not be granted additional time to regain compliance, though it may request a new hearing before any delisting. The company issued a press release on October 15, 2025, noting the compliance status.
bioAffinity Technologies, Inc. filed a prospectus supplement describing a common stock offering at an offering price of
bioAffinity Technologies, Inc. (BIAF) prospectus excerpts show a public offering priced at $2.50 per share with placement agent fees of $0.20 per share, producing proceeds before expenses of $2.30 per share and aggregate proceeds of $4,414,421.31. Historical net tangible book value per share was $0.20; the pro forma increase attributable to the offering is $0.99, producing a pro forma as-adjusted net tangible book value per share of $1.19. The filing notes Total capitalization of $(2,136,108) and references shares issuable upon conversion of 715.5 Series B Convertible Preferred shares at an initial conversion price of $6.90 per share.
Roberto Rios, a director of bioAffinity Technologies, Inc. (BIAF), filed an initial Form 3 disclosing beneficial ownership of 833 shares of the company's common stock. The event requiring the statement occurred on 08/12/2025 and the Form 3 bears a signature date of 09/25/2025. The filing indicates direct ownership and does not disclose any derivative securities or indirect holdings.
bioAffinity Technologies (BIAF) Form 3 — initial ownership disclosure. John J. Oppenheimer, listed as a Director, filed an initial Form 3 reporting that no securities are beneficially owned by him as of the event date 08/12/2025. The form shows the reporting relationship, the issuer symbol BIAF, and a signature dated 09/25/2025.
bioAffinity Technologies, Inc. filed an S-1 registration disclosing an assumed public offering price of $5.48 per share and pro forma capital impacts tied to that offering. The company reported a historical net tangible book value per share of $(1.30) as of June 30, 2025. Pro forma adjustments related to the offering increase net tangible book value by $2.06 to a pro forma as adjusted net tangible book value per share of $0.76. The filing shows a reported dilution to new investors of $4.72 per share. Additional disclosed items include conversion mechanics for Series B Convertible Preferred Stock (conversion price noted as $6.90 per share) and line items for additional paid-in capital and total capitalization figures included in the filing tables.
FAQ
What is the current stock price of bioAffinity Tech (BIAF)?
What is the market cap of bioAffinity Tech (BIAF)?
